Literature DB >> 29063296

Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies.

G Paul Wright1, Samantha Perkins1, Heather Jones1, Amer H Zureikat1, J Wallis Marsh2, Matthew P Holtzman1, Herbert J Zeh1, David L Bartlett1, James F Pingpank3,4.   

Abstract

BACKGROUND: Multifocal intrahepatic cholangiocarcinoma (ICC) has traditionally been treated with surgical resection when amenable. Intra-arterial therapy (IAT) for multifocal ICC has not been directly compared with surgical resection.
METHODS: A single-center, retrospective review of consecutive patients treated for multifocal ICC was conducted. Patients with distant metastases or treatment with systemic chemotherapy alone were excluded. Patients were divided into two groups: surgical resection versus IAT; IAT included transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and hepatic arterial infusion (HAI) pump therapy. Subjects were also analyzed by surgical resection, TACE, and HAI pump therapy.
RESULTS: Overall, 116 patients with multifocal ICC were studied, 57 in the surgical resection group and 59 in the IAT group (TACE = 41, HAI pump = 16, TARE = 2). The IAT group was characterized by a higher incidence of bilobar disease (88.1% vs. 47.4%, p < 0.001), larger tumors (median 10.6 vs. 7.5 cm, p = 0.004), higher incidence of macrovascular invasion (44.1% vs. 24.6%, p = 0.027), and higher rate of nodal metastases (57.6% vs. 28.6%, p = 0.002). Median overall survival for surgical resection was 20 months versus 16 months for IAT (p = 0.627). Multivariate analysis found that macrovascular invasion [hazard ratio (HR) 2.52, 95% confidence interval (CI) 1.56-4.09] and non-receipt of systemic chemotherapy (HR 3.81, 95% CI 2.23-6.52) were independent poor prognostic risk factors. Surgical resection was not associated with a survival advantage over IAT on multivariate analysis (p = 0.242).
CONCLUSION: Despite selection bias for use of surgical resection compared with IAT, no survival advantage was conferred in the treatment of multifocal ICC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29063296     DOI: 10.1245/s10434-017-6110-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.

Authors:  Cristina Mosconi; Leonardo Solaini; Giulio Vara; Nicolò Brandi; Alberta Cappelli; Francesco Modestino; Alessandro Cucchetti; Rita Golfieri
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-11       Impact factor: 2.740

2.  Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma.

Authors:  Pietro Addeo; Issam Jedidi; Andrea Locicero; François Faitot; Constantin Oncioiu; Alina Onea; Philippe Bachellier
Journal:  J Gastrointest Surg       Date:  2018-11-26       Impact factor: 3.452

3.  New insights into benefits of combination treatment with yttrium-90 and gemcitabine in patients with intrahepatic cholangiocarcinoma.

Authors:  Alexander I Damanakis; Florian Gebauer; Christiane Bruns
Journal:  J Gastrointest Oncol       Date:  2020-10

4.  Does resection improve overall survival for intrahepatic cholangiocarcinoma with nodal metastases?

Authors:  Patrick J Sweigert; Emanuel Eguia; Haroon Janjua; Sean P Nassoiy; Lawrence M Knab; Gerard Abood; Paul C Kuo; Marshall S Baker
Journal:  Surg Open Sci       Date:  2020-05-16

5.  Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

Authors:  Héloïse Bourien; Xavier Palard; Yan Rolland; Fanny Le Du; Luc Beuzit; Thomas Uguen; Samuel Le Sourd; Marc Pracht; Vincent Manceau; Astrid Lièvre; Karim Boudjema; Etienne Garin; Julien Edeline
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-29       Impact factor: 9.236

6.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

7.  Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma.

Authors:  Nikhil T Sebastian; Yubo Tan; Eric D Miller; Terence M Williams; Dayssy Alexandra Diaz
Journal:  Clin Transl Radiat Oncol       Date:  2019-07-26

8.  Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection.

Authors:  Hsiao-Tien Liu; Shao-Bin Cheng; Chia-Yu Lai; Yi-Ju Chen; Te-Cheng Su; Cheng-Chung Wu
Journal:  Therap Adv Gastroenterol       Date:  2020-12-10       Impact factor: 4.409

9.  Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.

Authors:  Eva Braunwarth; Peter Schullian; Moritz Kummann; Simon Reider; Daniel Putzer; Florian Primavesi; Stefan Stättner; Dietmar Öfner; Reto Bale
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

10.  Development and Validation of Nomograms for Predicting Cancer-Specific Survival in Elderly Patients with Intrahepatic Cholangiocarcinoma After Liver Resection: A Competing Risk Analysis.

Authors:  Tao Wang; Jinfu Zhang; Wanxiang Wang; Xianwei Yang; Junjie Kong; Shu Shen; Wentao Wang
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.